Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com
Active Lupus News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Active Lupus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Active Lupus Today - Breaking & Trending Today
Aurinia Pharmaceuticals Inc.: Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress
Use of LUPKYNIS was safe and well tolerated in patients for up to three years of treatment, with no new safety signals In AURORA 2, long-term treatment with LUPKYNIS led to a clinically relevant
Source: finanznachrichten.de